Proven performance, even in complex cases

No two anatomies are the same. No two cases follow the same path. Each brings its own demands and its own decisions to make.

The VBX Stent Graft is the first and only bridging stent graft approved for both fenestrated and branched endovascular aortic repair.1 With a unique, differentiated design, it delivers the flexibility and conformability to perform across anatomies—from routine to complex procedures. That performance is reinforced by independently validated, real-world clinical evidence for transparent data you can trust. Put it all together, and you’re ready for what faces you in complex aortic cases.

This FDA approval is an important milestone for physicians treating patients with complex aortic aneurysms. We are proud to bring U.S. physicians an indicated bridging stent option for both FEVAR and BEVAR and to continue innovating to advance treatment options for patients with complex aortic disease.”

Read the News Release
review-data-red

Extensively studied in real-world patients

With proven procedurala and clinical success in hundreds of FEVAR and BEVAR patients, in the Gore EMBRACE and EXPAND Registries, and in multiple publications, the VBX Stent Graft has been extensively studied in real-world patients, including unique and complex anatomies.3-8

The difference is in our data.2
broad-inclusion-red.svg

BROAD INCLUSION
MINIMAL EXCLUSION

Criteria representing real-world patient demographics

core-lab-red.svg

CORE LAB
ANALYZED

Independently validated to increase accuracy and reduce bias

multicenter-registry-red.svg

MULTICENTER
REGISTRY DESIGN

Strategically increasing the real-world population being studied

complex-aneurysms-red.svg

MIX OF COMPLEX
ANEURYSMS

The GORE EMBRACE Registry shows consistently strong clinical results in complex cases

1-year outcomes
Target vessel technical successa

100% FEVAR

99.6% BEVAR

Primary patency
 
1-year outcomes
3-year outcomes
FEVAR

99.4%

97.5%

BEVAR

98.9%

94.0%

 

Freedom from target vessel instability (fTVI)
 
1-year outcomes
3-year outcomes
FEVAR

96.6%

93.9%

BEVAR

94.5%

88.4%

1-year outcomes
Target vessel technical successa

100% FEVAR

100% BEVAR

Primary patency
 
1-year outcomes
3-year outcomes
FEVAR

100%

96.5%

BEVAR

96.0%

93.4%

 

Freedom from target vessel instability (fTVI)
 
1-year outcomes
3-year outcomes
FEVAR

100%

96.5%

BEVAR

96.0%

92.7%

Explore more clinical data

Unique Design, Versatile Applications

Close up of the VBX Product

Tap a point+in the image to view its details here

supportImage

Showing of

human-body-red

We’re driven by something different. Because what’s at stake is everything.

We’re focused on purposeful innovation and solving unique challenges, and we’re driven by physician partnerships that are built on collaboration and trust. Because doing the right thing for patients is right for us all.

+600,000

VBX Stent Grafts sold worldwide

Close up product shot of VBX

We work to have a positive impact one patient at a time

+20 years

Underlying materials and technology proven across a range of indications

Watermark with text that read: 50 Years of Medical Innovation

Related to this product

a. Based on previously collected clinical data. Evaluation of the reduced-profile delivery system is ongoing.
 

  1. W. L. Gore & Associates. GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Instructions for Use. 2026. MD169334, Rev. 9; MD208864, Rev. 3.
  2. Dioni P, Wanhainen A, Budtz-Lilly J, Dias N, Bonny T, Bertoglio L; EMBRACE Study Investigator. GORE VIABAHN VBX Balloon-Expandable Endoprostheses as a bridging stent with branched and fenestrated endografts in the endovascular treatment of aortic aneurysms: protocol for a retrospective multicenter registry (EMBRACE study). JMIR Res Protoc. 2026;15:e78970. doi:10.2196/78970
  3. Real-world data collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis when used as a bridging stent with branched and fenestrated endografts in the treatment of aortic aneurysms involving the renal-mesenteric arteries (EMBRACE). ClinicalTrials.gov identifier: NCT05143138. Updated September 21, 2026. Accessed September 28, 2026. https://clinicaltrials.gov/study/NCT05143138
  4. Post-market registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis implanted in peripheral vessels (EXPAND). ClinicalTrials.gov identifier: NCT03720704. Updated April 14, 2026. Accessed September 28, 2026. https://clinicaltrials.gov/study/NCT03720704
  5. Usai MV, Gargiulo M, Haulon S, et al. A three-year experience with the balloon expandable GORE VIABAHN VBX in the treatment of thoraco-abdominal aortic aneurysms within the EXPAND trial. J Vasc Surg. 2025;81(2):319-323.e1. doi:10.1016/j.jvs.2024.10.002
  6. Kappe KO, van Knippenberg SEM, Tran BL, et al. Mid-term outcomes of the VIABAHN Balloon-Expandable Endoprosthesis as bridging stent graft for fenestrated and branched endovascular aortic repair. J Endovasc Ther. 2026;33(3):1354-1362. doi:10.1177/15266028241300005
  7. Torsello GB, Pitoulias A, Litterscheid S, et al. Performance of the GORE VBX Balloon Expandable Endoprosthesis as bridging stent-graft in branched endovascular aortic repair for thoracoabdominal aneurysms. J Endovasc Ther. 2021;28(4):549-554. doi:10.1177/15266028211010455
  8. Di Domenico R, Esposito D, Speziali S, et al. The GORE VIABAHN Balloon-Expandable Stent Graft as a bridging stent in complex endovascular aortic procedures at 3 years performs better in fenestrations. J Vasc Surg. 2024;80(6):1650-1657.e1. doi:10.1016/j.jvs.2024.08.011
  9. Data on file. W. L. Gore & Associates; 2026. EMBRACE_EXPAND through 3-5yrs.
  10. Bard Peripheral Vascular. LIFESTREAM® Balloon Expandable Vascular Covered Stent Instructions for Use. Bard Peripheral Vascular; 2019. BAW1345700, Rev 5.
  11. Atrium Medical Corporation. iCAST Covered Stent System Instructions for Use. Atrium Medical Corporation; 2025. EL012022, Rev AA.
     
IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

INDICATIONS FOR USE IN THE US: The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5 mm - 13 mm and lesion lengths up to 110 mm, including lesions at the aortic bifurcation.

The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is indicated to maintain visceral artery perfusion as a bridging stent in:

  • fenestrated endovascular aortic aneurysm repair with 6-8 mm diameter fenestrations
  • branched endovascular aortic aneurysm repair with 6-8 mm diameter branches (e.g. portals, cuffs, or directional branches) that are at least 10 mm in length.

Bridging stent use is limited to aortic endovascular graft systems wherein safety and effectiveness has been demonstrated.   

CONTRAINDICATIONS: Do not use the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Patients with known sensitivities or allergies to the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis materials including expanded polytetrafluoroethylene (ePTFE), fluorinated ethylene propylene (FEP), stainless steel, and heparin.

The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is not authorized for use with thoracoabdominal and pararenal branched devices indicated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a branch component in Canada.

26PL1148-EN01 MAT-1388-1